Genfit makes $135M debut on Nasdaq
The French company, developing a drug to treat nonalcoholic steatohepatitis, or NASH, announced the pricing of its shares at $20.32 apiece.
Digital health leader Derek Newell joins Virta Health as Head of Commercial
Prior to founding health benefits platform Jiff (which was acquired by Castlight in 2017), Newell worked for years in the remote care monitoring and chronic disease management space.
presented by
A Path to Healing: Discovering Arizona’s PTSD Treatment Centers
Explore top PTSD treatment centers in Arizona, offering personalized care, holistic therapies and expert support to help individuals heal and reclaim their lives.
Chinese-American startup Terns Pharmaceuticals raises $80M for NASH, cancer drugs
The company joins a growing wave of firms developing drugs for the disease, which has no approved treatments. It expects to enter two drugs into the clinic next year.
Novartis, Pfizer partner to develop drugs for NASH
The companies will run clinical trials combining Novartis' tropifexor with any one of several Pfizer drugs under development for the disease, which lacks approved treatments.
OrbiMed launches 89Bio with $60M Series A round to develop Teva’s NASH drug
The new company is headquartered in San Francisco, with R&D in Israel and has launched a Phase I study of BIO89-100, formerly TEV-47948.
Ambys Medicines garners $140 million to develop chronic liver disease treatments
The company secured $60 million in a Series A round from Third Rock and Takeda, plus a partnership with Takeda.
presented by
The Top 5 Home Care Franchise Opportunities in the U.S.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.